AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31978580 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in codon 90 of the gyrA gene
Number of subjects: 542
Study 29468748 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diet (0.8 g protein kg‐1 body weight: 35% animal proteins, 35% soy protein, 30% vegetable proteins)
Number of subjects: 60
Study 27763459 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention for smoking cessation
Number of subjects: 400
Study 27763459 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based intervention for smoking cessation
Number of subjects: 400
Study 27763459 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (individual and group-based)
Number of subjects: 400
Study 27763459 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater attendance in sessions
Number of subjects: 400
Study 24755713 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated (INT) risk education protocol
Number of subjects: 530
Study 24755713 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific (DSE) risk education protocol
Number of subjects: 530
Study 24755713 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 530
Study 24755713 — intervention group
Group type: COMPARATOR
Intervention: INT group
Number of subjects: 530
Study 24755713 — intervention group
Group type: COMPARATOR
Intervention: DSE group
Number of subjects: 530
Study 22536597 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system
Number of subjects: 90
Study 22536597 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-etch-and-rinse adhesive system
Number of subjects: 90
Study 22536597 — intervention group
Group type: COMPARATOR
Intervention: Control group (unbleached teeth)
Number of subjects: 90
Study 22536597 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed group (DG)
Number of subjects: 90
Study 19842609 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal relaxing incision (LRI) combined with bimanual microincision cataract surgery (MICS)
Number of subjects: 0
Study 19842609 — intervention group
Group type: COMPARATOR
Intervention: Bimanual microincision cataract surgery (MICS) without LRI (non-LRI group)
Number of subjects: 0
Study 19842609 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal relaxing incision (LRI) combined with bimanual MICS
Number of subjects: 0
Study 18277214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiplegia rehabilitation program with analgesic and calcitonin therapy, elevation, range of movement therapy, and contrast baths.
Number of subjects: 80
Study 18277214 — intervention group
Group type: COMPARATOR
Intervention: Hemiplegia rehabilitation program without additional therapies (control group).
Number of subjects: 80
Study 18277214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (study and control) regarding Ashworth scale.
Number of subjects: 80
Study 18277214 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group comparison for MAS ULF, MAS HM, and MAS AHA.
Number of subjects: 80
Study 15689289 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin for 10 days
Number of subjects: 135
Study 15689289 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 135
Study 17986534 — intervention group
Group type: EXPERIMENTAL
Intervention: Carex disconnect system
Number of subjects: 363
Study 17986534 — intervention group
Group type: COMPARATOR
Intervention: Ultra disconnect system
Number of subjects: 363
Study 11078235 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% CHO diet
Number of subjects: 8
Study 11078235 — intervention group
Group type: COMPARATOR
Intervention: 40% CHO diet
Number of subjects: 8
Study 8653989 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (100 mg/day for 16 days)
Number of subjects: 15
Study 8653989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1576053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0
Study 6362999 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intermittent positive pressure breathing (IPPB) for four days with physiotherapy
Number of subjects: 30
Study 6362999 — intervention group
Group type: COMPARATOR
Intervention: Postoperative care without IPPB
Number of subjects: 30
Study 31829237 — intervention group
Group type: EXPERIMENTAL
Intervention: specialist palliative care consultation
Number of subjects: 236
Study 31829237 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 236
Study 29183956 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced video
Number of subjects: 0
Study 29183956 — intervention group
Group type: COMPARATOR
Intervention: Health marketing video
Number of subjects: 0
Study 29183956 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSW
Number of subjects: 0
Study 29183956 — intervention group
Group type: EXPERIMENTAL
Intervention: G-formula
Number of subjects: 0
Study 27061740 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (INT)
Number of subjects: 152
Study 27061740 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 152
Study 25301015 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform luminous background during the retention interval of the visual working memory task
Number of subjects: 0
Study 25301015 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased background luminance during imagery generation
Number of subjects: 0
Study 25301015 — intervention group
Group type: COMPARATOR
Intervention: Verbal number working memory task
Number of subjects: 0
Study 22386382 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 28
Study 22386382 — intervention group
Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 28
Study 20855823 — intervention group
Group type: EXPERIMENTAL
Intervention: mGEMOX (gemcitabine 900 mg/m2 and oxaliplatin 80 mg/m2 IV infusion on days 1 and 8 every 3 weeks for maximum of six cycles)
Number of subjects: 81
Study 20855823 — intervention group
Group type: EXPERIMENTAL
Intervention: FUFA (fluorouracil 425 mg/m2 and folinic acid 20 mg/m2 IV bolus weekly for 30 weeks)
Number of subjects: 81
Study 20855823 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 81
Study 17912635 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily for 5 years
Number of subjects: 5187
Study 17912635 — intervention group
Group type: COMPARATOR
Intervention: Letrozole after unblinding
Number of subjects: 5187
Study 17912635 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 5187
Study 16376645 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplements
Number of subjects: 312
Study 16376645 — intervention group
Group type: COMPARATOR
Intervention: No antioxidant supplements
Number of subjects: 312
Study 12197366 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 1008
Study 12197366 — intervention group
Group type: COMPARATOR
Intervention: Continuous combined hormone replacement therapy (ccHRT)
Number of subjects: 1008
Study 12197366 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 1008
Study 10729965 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in combination with manual lymph drainage
Number of subjects: 35
Study 10729965 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 35
Study 9127079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular instillation of 20 mL bupivacaine (0.25%) and local infiltration of 20 mL bupivacaine (0.5%)
Number of subjects: 40
Study 9127079 — intervention group
Group type: COMPARATOR
Intervention: Saline solution injection
Number of subjects: 40
Study 1436589 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide, 400 mg b.i.d. i.m.
Number of subjects: 47
Study 1436589 — intervention group
Group type: COMPARATOR
Intervention: Heparin calcium, 5000 IU b.i.d. s.c.
Number of subjects: 47
Study 3466089 — intervention group
Group type: EXPERIMENTAL
Intervention: Aural toilet
Number of subjects: 3500
Study 3466089 — intervention group
Group type: COMPARATOR
Intervention: Ototopical boric acid
Number of subjects: 3500
Study 3466089 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside solution
Number of subjects: 3500
Study 3466089 — intervention group
Group type: COMPARATOR
Intervention: Oral antianaerobic clindamycin
Number of subjects: 3500
Study 3466089 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental tuition in aural cleaning, avoidance of ear water entry, nose blowing and breathing
Number of subjects: 3500
Study 30922377 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 mcg daily for three months
Number of subjects: 23
Study 30922377 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol 1000 IU daily for three months
Number of subjects: 23
Study 30371299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg/d for 24 weeks
Number of subjects: 140
Study 30371299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 26047775 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment + GRACE scoring system
Number of subjects: 572
Study 26047775 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 572
Study 26047775 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE score >140
Number of subjects: 572
Study 26047775 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 572
Study 26047775 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary referral from a non-PCI cardiology department
Number of subjects: 572
Study 25440794 — intervention group
Group type: EXPERIMENTAL
Intervention: ALDH(br) cells delivered by direct intramuscular injections
Number of subjects: 80
Study 25440794 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 80
Study 23140761 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch
Number of subjects: 918
Study 23140761 — intervention group
Group type: COMPARATOR
Intervention: Resistant-starch placebo
Number of subjects: 918
Study 20808210 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed jaw-thrust technique
Number of subjects: 42
Study 20808210 — intervention group
Group type: COMPARATOR
Intervention: One-handed 'EC-clamp' technique
Number of subjects: 42
Study 20808210 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of techniques
Number of subjects: 42
Study 18958560 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/m2 paclitaxel administered weekly
Number of subjects: 68
Study 15908042 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy (mitomycin, ifosfamide and cisplatin (MIC) or mitomycin, vinblastine and cisplatin (MVP)) followed by surgery (CT-S)
Number of subjects: 48
Study 15908042 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy (RT)
Number of subjects: 48
Study 11796917 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 1635
Study 11796917 — intervention group
Group type: EXPERIMENTAL
Intervention: Marrow in vitro purging with mafosfamide
Number of subjects: 1635
Study 11796917 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy post-ASCT
Number of subjects: 1635
Study 11796917 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCT
Number of subjects: 1635
Study 10615229 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2 every 3 weeks, n = 143)
Number of subjects: 283
Study 10615229 — intervention group
Group type: COMPARATOR
Intervention: Sequential methotrexate and 5-fluorouracil (MF; 200 mg/m2 and 600 mg/m2 every 3 weeks, n = 139)
Number of subjects: 283
Study 7532395 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser treatment covering the foveal side with a narrow (< or = 100 microns) border of treatment to adjacent uninvolved retina.
Number of subjects: 353
Study 7532395 — intervention group
Group type: COMPARATOR
Intervention: Krypton laser treatment with either some of the foveal side of the lesion left untreated or a wide border of treatment on the foveal side.
Number of subjects: 353
Study 7532395 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser treatment in eyes with neovascular lesions 200 to 500 microns from the center of the foveal avascular zone.
Number of subjects: 353
Study 7532395 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser treatment in eyes with lesions in either distance category in the Age‐Related Macular Degeneration Study.
Number of subjects: 353
Study 2039294 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy and surgery (ES&S)
Number of subjects: 52
Study 2039294 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (SA)
Number of subjects: 52
Study 31414974 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient 25(OH)D levels (30-100 ng/mL)
Number of subjects: 101
Study 31414974 — intervention group
Group type: COMPARATOR
Intervention: Active vitiligo (associated with 25(OH)D deficiency ≤20 ng/mL)
Number of subjects: 101
Study 31414974 — intervention group
Group type: COMPARATOR
Intervention: Active vitiligo (associated with 25(OH)D insufficiency 21-29 ng/mL)
Number of subjects: 101
Study 31414974 — intervention group
Group type: COMPARATOR
Intervention: Stable vitiligo (associated with sufficient 25(OH)D levels 30-100 ng/mL)
Number of subjects: 101
Study 31358008 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/18/9.6 μg
Number of subjects: 456
Study 31358008 — intervention group
Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Number of subjects: 456
Study 31358008 — intervention group
Group type: COMPARATOR
Intervention: GFF MDI 18/9.6 μg
Number of subjects: 456
Study 31358008 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (BGF MDI, BFF MDI, GFF MDI)
Number of subjects: 456
Study 31358008 — intervention group
Group type: COMPARATOR
Intervention: GFF MDI
Number of subjects: 456
Study 31358008 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI
Number of subjects: 456
Study 31358008 — intervention group
Group type: EXPERIMENTAL
Intervention: BFF MDI
Number of subjects: 456
Study 27775484 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 540
Study 27775484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 540
Study 27775484 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting PA guidelines
Number of subjects: 540
Study 27775484 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA by gender
Number of subjects: 540
Study 25297681 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 60
Study 25297681 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 60
Study 24284096 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral analysis of blood plasma and cellular components
Number of subjects: 0
Study 24284096 — intervention group
Group type: COMPARATOR
Intervention: Common techniques for detection (complete blood cell count, electrophoresis, high performance liquid chromatography)
Number of subjects: 0
Study 20609546 — intervention group
Group type: EXPERIMENTAL
Intervention: Entertainment-based decision aid for breast cancer treatment along with usual care
Number of subjects: 0
Study 20609546 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 19741202 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for acute phase response using reported recent fever, AGP, and CRP
Number of subjects: 690
Study 19741202 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for acute phase response using reported recent fever and AGP
Number of subjects: 690
Study 19741202 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for acute phase response using CRP and/or AGP
Number of subjects: 690
Study 19741202 — intervention group
Group type: COMPARATOR
Intervention: Reported recent fever alone
Number of subjects: 690
Study 19741202 — intervention group
Group type: EXPERIMENTAL
Intervention: AGP
Number of subjects: 690
Study 19741202 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 690
Study 19741202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin
Number of subjects: 690
Study 19741202 — intervention group
Group type: EXPERIMENTAL
Intervention: ZPP, TfR, and EPO
Number of subjects: 690
Study 17878636 — intervention group
Group type: EXPERIMENTAL
Intervention: 50/50 premixed insulin lispro twice-daily
Number of subjects: 30
Study 17878636 — intervention group
Group type: COMPARATOR
Intervention: premixed human insulin (control group)
Number of subjects: 30
Study 15520061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine (VRL) 30 mg/m2 on days 1 and 8 every 3 weeks plus hydrocortisone 40 mg/day
Number of subjects: 414
Study 15520061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine (VRL) plus hydrocortisone
Number of subjects: 414
Study 15520061 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone alone
Number of subjects: 414
Study 11573526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group 1, 14 patients)
Number of subjects: 28
Study 11573526 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia (group 2, 14 patients)
Number of subjects: 28
Study 9930042 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse run clinics
Number of subjects: 1173
Study 7528307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg
Number of subjects: 6
Study 7528307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 6
Study 7528307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3381992 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g dipyrone
Number of subjects: 18
Study 3381992 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g dipyrone
Number of subjects: 18
Study 3381992 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g dipyrone
Number of subjects: 18
Study 3381992 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g dipyrone
Number of subjects: 18
Study 3381992 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g dipyrone
Number of subjects: 18
Study 3381992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31780037 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint gel applied three times a day for up to 14 days
Number of subjects: 150
Study 31780037 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 150
Study 28372983 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting with nitinol self-expanding stents
Number of subjects: 100
Study 28372983 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 100
Study 25586335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesion abciximab
Number of subjects: 0
Study 25586335 — intervention group
Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 0
Study 25586335 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration
Number of subjects: 0
Study 25586335 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak CK‐MB ≥300 IU/L
Number of subjects: 0
Study 25586335 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐MB measurement
Number of subjects: 0
Study 24183034 — intervention group
Group type: EXPERIMENTAL
Intervention: CILA (Cookgas intubating laryngeal airway)
Number of subjects: 60
Study 24183034 — intervention group
Group type: COMPARATOR
Intervention: FT-LMA (Fastrach intubating laryngeal mask airway)
Number of subjects: 60
Study 21969009 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5-10 mg/d)
Number of subjects: 1761
Study 21969009 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10-40 mg/d)
Number of subjects: 1761
Study 21969009 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (12.5-25 mg/d)
Number of subjects: 1761
Study 18240352 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention and medication
Number of subjects: 262
Study 18240352 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 262
Study 16538423 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared LED treatment (160 mW, 6 min, energy density 3.2 J/cm²)
Number of subjects: 32
Study 16538423 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (sham irradiation)
Number of subjects: 32
Study 14522567 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (C) or Enalapril (E)
Number of subjects: 426
Study 14522567 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan + Enalapril (C+E)
Number of subjects: 426
Study 14522567 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan + Metoprolol/Enalapril + Metoprolol (C+M/E+M)
Number of subjects: 426
Study 14522567 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan + Enalapril + Metoprolol (C+E+M)
Number of subjects: 426
Study 11033843 — intervention group
Group type: EXPERIMENTAL
Intervention: BALF‐IL‐12 in sarcoidosis patients (41.3 +/- 43.9 pg/ml)
Number of subjects: 36
Study 11033843 — intervention group
Group type: EXPERIMENTAL
Intervention: BALF‐IL‐12 in patients with active disease (71.3 +/- 54.3 pg/ml)
Number of subjects: 36
Study 11033843 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with number of T4 cells
Number of subjects: 36
Study 11033843 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with total cell number, number and percentage of lymphocytes
Number of subjects: 36
Study 11033843 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with AM
Number of subjects: 36
Study 11033843 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with soluble ICAM‐1 levels in serum
Number of subjects: 36
Study 11033843 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with soluble ICAM‐1 levels in BALF
Number of subjects: 36
Study 11033843 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BALF‐IL‐12 with ICAM‐1 expression of AM
Number of subjects: 36
Study 11033843 — intervention group
Group type: EXPERIMENTAL
Intervention: AM of sarcoidosis (133 +/- 177 pg/ml)
Number of subjects: 36
Study 8969784 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 721
Study 8969784 — intervention group
Group type: COMPARATOR
Intervention: Carotid arteriography
Number of subjects: 721